Article Text

Download PDFPDF
Chronic kidney disease in cats attending primary care practice in the UK: a VetCompassTM study
  1. Megan Conroy1,
  2. David C Brodbelt1,
  3. Dan O’Neill1,
  4. Yu-Mei Chang2 and
  5. Jonathan Elliott3
  1. 1 Department of Veterinary Clinical Sciences, Royal Veterinary College—Hawkshead Campus, Hatfield, UK
  2. 2 Research Support Office, Royal Veterinary College, London, UK
  3. 3 Department of Veterinary Basic Sciences, Royal Veterinary College, London, UK
  1. E-mail for correspondence; mconroy3{at}


Chronic kidney disease (CKD) is a frequent diagnosis in cats attending primary care practice and the most frequent cause of death in cats aged over five years, yet there is limited published research for CKD in cats attending primary care practice. This study aimed to estimate the prevalence of CKD and investigate risk factors for diagnosis and survival of cats diagnosed with CKD in UK primary care practices. The study included cats attending VetCompassTM practices from January 1, 2012 to December 31, 2013. A nested case-control and cohort study were undertaken. From 353,448 cats attending 244 clinics, the prevalence of CKD was estimated as 1.2 per cent (95 per cent CI 1.1 per cent to 1.3 per cent). Most cats with CKD had clinical signs at diagnosis (66.6 per cent). Few cats underwent investigations or monitoring of serum creatinine (32.6 per cent), urine protein:creatinine ratio (14.9 per cent) or blood pressure measurement (25.6 per cent). A proprietary renal diet was the most frequently prescribed management (63.8 per cent). Median survival time following diagnosis was 388 days (IQR 88–1042 days). This study provides generalisable evidence from the wider cat population to aid veterinarians in improved diagnosis and management of CKD that can benefit the health and welfare of cats with CKD in the UK.

  • ckd
  • renal disease
  • feline
  • prevalence
  • vetcompass
  • epidemiology
View Full Text

Statistics from


  • Funding This work was supported by a grant from Ceva Santé Animale. Ceva had no involvement in the study design, collection, analysis and interpretation of the data or the writing of the report.

  • Competing interests JE has received grant funding from and acted as a consultant for Ceva Animal Health, Novartis Animal Health/Elanco, Boehringer Ingelheim and Royal Canin. This works conforms to the STROBE guidelines for reporting observational epidemiological studies.

  • Ethics approval Ethics approval was provided by the Royal Veterinary College Clinical Research Ethical Review Board (URN M2015 0050).

  • Provenance and peer review Not commissioned; externally peer reviewed.

  • Data sharing statement Anonymised data used to generate the results of this research are available from

  • Presented at This research was presented at the Society for Veterinary Epidemiology and Preventative Medicine Annual Meeting 2017.

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.